blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3169361

EP3169361 - COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 30.09.2024
FormerThe patent has been granted
Status updated on  17.05.2019
FormerGrant of patent is intended
Status updated on  14.01.2019
FormerExamination is in progress
Status updated on  12.01.2018
FormerRequest for examination was made
Status updated on  21.04.2017
FormerThe international publication has been made
Status updated on  19.12.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2017/21]
Inventor(s)01 / JUNTTILA, Melissa
c/o Genentech Inc.
1 Dna Way
South San Francisco, CA 94080 / US
 [2017/21]
Representative(s)Brodbeck, Michel
F. Hoffmann-La Roche AG
Patent Department
Grenzacherstrasse 124
4070 Basel / CH
[2017/21]
Application number, filing date15747647.415.07.2015
[2017/21]
WO2015US40582
Priority number, dateUS201462024988P15.07.2014         Original published format: US 201462024988 P
[2017/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016011160
Date:21.01.2016
Language:EN
[2016/03]
Type: A1 Application with search report 
No.:EP3169361
Date:24.05.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 21.01.2016 takes the place of the publication of the European patent application.
[2017/21]
Type: B1 Patent specification 
No.:EP3169361
Date:19.06.2019
Language:EN
[2019/25]
Search report(s)International search report - published on:EP21.01.2016
ClassificationIPC:A61K39/395, C07K16/28, A61P35/00
[2019/03]
CPC:
A61K31/4523 (EP,CN,IL,US); A61K39/3955 (IL,US); A61K39/39558 (EP,CN,IL,KR,US);
A61K45/06 (CN,KR); A61K39/395 (RU); A61P35/00 (EP,IL,RU);
A61P35/04 (EP,IL); A61P43/00 (EP,IL); C07K16/2803 (IL,US);
C07K16/2827 (EP,IL,KR,US); A61K2039/505 (EP,IL,US); A61K2039/542 (IL,US);
A61K2300/00 (IL,KR); C07K2317/52 (EP,IL,US); C07K2317/56 (IL,US);
C07K2317/72 (EP,IL,US); C07K2317/73 (EP,IL,KR,US); C07K2317/76 (EP,IL,US) (-)
C-Set:
A61K31/4523, A61K2300/00 (CN);
A61K39/39558, A61K2300/00 (CN,EP,US)
Former IPC [2017/21]A61K39/395, C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/21]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:ZUSAMMENSETZUNGEN ZUR KREBSBEHANDLUNG MIT PD-1-ACHSENBINDENDEN ANTAGONISTEN UND MEK-INHIBITOREN[2017/21]
English:COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS[2017/21]
French:COMPOSITIONS DE TRAITEMENT DU CANCER À L'AIDE D'ANTAGONISTES DE LIAISON À L'AXE PD-1 ET D'INHIBITEURS DE MEK[2017/21]
Entry into regional phase15.02.2017National basic fee paid 
15.02.2017Designation fee(s) paid 
15.02.2017Examination fee paid 
Examination procedure19.12.2016Date on which the examining division has become responsible
15.02.2017Examination requested  [2017/21]
29.08.2017Amendment by applicant (claims and/or description)
11.01.2018Despatch of a communication from the examining division (Time limit: M04)
04.05.2018Reply to a communication from the examining division
09.11.2018Despatch of a communication from the examining division (Time limit: M01)
30.11.2018Reply to a communication from the examining division
15.01.2019Communication of intention to grant the patent
08.05.2019Fee for grant paid
08.05.2019Fee for publishing/printing paid
08.05.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19172991.2  / EP3563870
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Fees paidRenewal fee
10.07.2017Renewal fee patent year 03
10.07.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.07.2015
AL19.06.2019
CY19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
MK19.06.2019
MT19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
IE15.07.2019
LU15.07.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
[2022/31]
Former [2021/34]HU15.07.2015
AL19.06.2019
CY19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
MT19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
IE15.07.2019
LU15.07.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2021/33]HU15.07.2015
AL19.06.2019
CY19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
IE15.07.2019
LU15.07.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2021/26]AL19.06.2019
CY19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
IE15.07.2019
LU15.07.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/37]AL19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
RS19.06.2019
SI19.06.2019
SK19.06.2019
SM19.06.2019
IE15.07.2019
LU15.07.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/36]AL19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
IE15.07.2019
LU15.07.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/27]AL19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
LU15.07.2019
BG19.09.2019
NO19.09.2019
PT21.10.2019
IS24.02.2020
Former [2020/24]AL19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
BG19.09.2019
NO19.09.2019
PT21.10.2019
IS24.02.2020
Former [2020/22]AL19.06.2019
CZ19.06.2019
DK19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/17]AL19.06.2019
CZ19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
MC19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/14]AL19.06.2019
CZ19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
SK19.06.2019
SM19.06.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/12]AL19.06.2019
CZ19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
SK19.06.2019
BG19.09.2019
NO19.09.2019
IS19.10.2019
PT21.10.2019
Former [2020/11]AL19.06.2019
CZ19.06.2019
EE19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
SK19.06.2019
BG19.09.2019
NO19.09.2019
PT21.10.2019
Former [2020/10]AL19.06.2019
CZ19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
BG19.09.2019
NO19.09.2019
PT21.10.2019
Former [2020/09]AL19.06.2019
CZ19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
BG19.09.2019
NO19.09.2019
Former [2019/52]AL19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
BG19.09.2019
NO19.09.2019
Former [2019/50]AL19.06.2019
FI19.06.2019
HR19.06.2019
LT19.06.2019
LV19.06.2019
RS19.06.2019
NO19.09.2019
Former [2019/47]FI19.06.2019
LT19.06.2019
NO19.09.2019
Cited inInternational search[XI]WO2013019906  (GENENTECH INC [US], et al);
by applicantWO8403506
 WO8403564
 US4708871
 US4816567
 US4833092
 EP0404097
 WO9110741
 WO9311161
 US5223409
 US5403484
 US5428130
 US5475096
 US5545807
 US5545806
 US5556762
 US5569825
 WO9634096
 WO9633735
 US5571689
 US5625126
 US5633425
 US5641870
 US5661016
 US5663143
 US5750373
 WO9824893
 US6075181
 US6150584
 WO03077914
 WO2004042072
 WO2004092219
 WO2005121142
 US6982321
 US7087409
 WO2006121168
 WO2007002325
 WO2007002433
 WO2007005874
 WO2007044515
 WO2007096259
 WO2008024725
 US7491829
 WO2009021887
 WO2009085983
 WO2009101611
 WO2009111278
 WO2009111279
 WO2009111277
 WO2009111280
 WO2009114335
 WO2010027827
 WO2010077634
 WO2011066389
 WO2011066342
 US2013034559
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.